Home
Company
About Us
Company Profile
Management
Board of Directors
Scientific Advisory Board
Ethics Statement
Legal Statement
Company Overview
SEC Filings - Links
SEC Filings - XBRL
News
Current Press Releases
Press Release Archive
ChartPoppers.com Interview
Australian Influenza Study Report
Investors
Investor Information
RSS News Feeds
Investor Kit
Oral Interferon
Why Low-Dose Oral Interferon
Interferon Facts
Disease Information
Clinical Trials
Research Projects
Key Publications
Patents
Development Partners
MAXISAL®
Do You Have Dry Mouth
MAXISAL® Retailers
MAXISAL® Publications & Patents
MAXISAL® Overview
Contact Us
Current Press Releases
Press Release Archive
More Articles...
Amarillo Biosciences Selects Accelovance for its Next Influenza Study
Amarillo Biosciences Reaches Enrollment Goal in Australian Influenza Phase 2 Clinical Trial
Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza
Amarillo Biosciences’ Phase 2 Australian Clinical Study Of Interferon As A Preventative Agent Against H1N1 Flu Virus And Other Cold And Flu Viruses Reaches Midway Point
Amarillo Biosciences Reports on Research Supporting Use of Interferon
Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit in Preventing Influenza-like Illness in Older Participants
Dr. Manfred Beilharz to Present Oral Interferon Study Findings at 3rd World Summit of Antivirals in Busan, Korea
Report on Australian Oral Interferon Influenza Study is Submitted and Available Online
Viral Serology Confirms that Oral Interferon Reduces Incidence of Cold and Flu Symptoms in Australian Phase 2 Clinical Trial
Amarillo Biosciences’ Dietary Supplement for Dry Mouth Maxisal Launched in Germany
Amarillo Biosciences to Supply Zydus Cadila, India’s Fifth Largest Pharmaceutical Company, with Dietary Supplement Maxisal for Indian Market
Amarillo Biosciences Releases Corporate Progress Report
Amarillo Biosciences Teams with Colorado Serum Company to Manufacture Immune-Boosting Bovine Protein Extract for Animal and Human Health Markets
Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
Amarillo Biosciences’ Live Interview Available on ChartPoppers.com
Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO Dr. Joseph Cummins Remains President and COO